Anthony W. Amato
Chief Executive Officer
After practicing law for several years, Tony started his career in pharmaceuticals in business development at Barr Labs. During his tenure at the company, Barr acquired proprietary women’s health products, Plan B and Paragard, and in-licensed transdermals, ophthalmics and nasal sprays, rapidly expanding beyond its generic solid oral dose portfolio. Barr was eventually acquired by Teva for $7.5B in 2008. Tony next headed up US business development at Lupin Pharmaceuticals and led the aggressive expansion into high margin brand products, diversifying Lupin’s product portfolio. In 2014 Tony joined Alvogen and rose to the position of Sr. Vice President Business Development and Alliance Management, completing multiple transactions and deploying over $500M capital in five years to expand the generic portfolio into injectables and inhalation drug forms and grow its branded business, Almatica, through the acquisition of highly profitable mature products and patent protected Psychiatry/CNS approved and pipeline products as well as biosimilars.
Tony was named CEO of Virtus in 2022 and is re-positioning the company by building verticals focused on retail and institutional generics, brands, consumer health and biosimilars, employing innovative business models and deal structures that will benefit its partners and, ultimately, patients.